The estimated Net Worth of Victoria L. Brown is at least $1.08 Million dollars as of 17 June 2022. Ms. Brown owns over 2,698 units of Apellis Pharmaceuticals Inc stock worth over $958,003 and over the last 4 years she sold APLS stock worth over $121,410. In addition, she makes $0 as Senior Vice President and Program Team Lead – Systemic Chronic at Apellis Pharmaceuticals Inc.
Sign up
Ms. Brown APLS stock SEC Form 4 insiders trading
Victoria has made over 2 trades of the Apellis Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 2,698 units of APLS stock worth $121,410 on 17 June 2022.
The largest trade she's ever made was exercising 12,000 units of Apellis Pharmaceuticals Inc stock on 7 October 2020 worth over $227,760. On average, Victoria trades about 1,131 units every 48 days since 2020. As of 17 June 2022 she still owns at least 24,974 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Ms. Brown stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Victoria Brown biography
Victoria Brown serves as Senior Vice President, Program Team Lead – Systemic Chronic of the Company. Prior to joining our company, from December 2009 to January 2019, Ms. Brown held a variety of executive roles at Biogen Inc, or Biogen, including Senior Director, Portfolio and Pipeline Brand Lead from August 2017 to January 2019, Director, US Brand Lead from September 2015 to July 2017, and Director, Global Brand Lead, from September 2014 to September 2015. Before Biogen, Ms. Brown spent 10 years at Janssen Pharmaceuticals holding numerous leadership positions with increasing levels of scope and responsibility. Ms. Brown has a B.S. (Hons) in health sciences from the University of Aberdeen
How old is Victoria Brown?
Victoria Brown is 41, she's been the Senior Vice President and Program Team Lead – Systemic Chronic of Apellis Pharmaceuticals Inc since 2020. There are 23 older and no younger executives at Apellis Pharmaceuticals Inc. The oldest executive at Apellis Pharmaceuticals Inc is Gerald Chan, 69, who is the Independent Chairman of the Board.
What's Victoria Brown's mailing address?
Victoria's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Insiders trading at Apellis Pharmaceuticals Inc
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois, and Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
What does Apellis Pharmaceuticals Inc do?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
What does Apellis Pharmaceuticals Inc's logo look like?
Complete history of Ms. Brown stock trades at Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc executives and stock owners
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Cedric Francois,
President, Chief Executive Officer, Co-Founder, Director -
Lukas Scheibler,
Chief Innovation Officer -
Federico Grossi,
Chief Medical Officer -
Thomas Lackner,
Senior Vice President, Head of Europe -
Pascal Deschatelets,
Co-Founder, Chief Operating Officer -
Timothy Sullivan,
Chief Financial Officer, Treasurer -
Dr. Cedric Francois,
Co-Founder, Pres, CEO & Director -
Timothy E. Sullivan,
Chief Financial Officer -
Dr. Pascal Deschatelets Ph.D.,
Co-Founder & Chief Scientific Officer -
Adam J. Townsend,
Chief Commercial Officer -
Gerald Chan,
Independent Chairman of the Board -
Stephanie O'Brien,
Independent Director -
Alec Machiels,
Independent Director -
A. Sinclair Dunlop,
Independent Director -
Alec Machiels J.D., MBA,
Co-Founder & Independent Director -
Sam Martin,
IR Contact Officer -
Paul Fonteyne,
Independent Director -
Adam Townsend,
Chief Commercial Officer -
David Watson,
General Counsel, Vice President of Corporate Development -
Nicole Perry,
Vice President - Finance -
Victoria Brown,
Senior Vice President, Program Team Lead – Systemic Chronic -
David O. Watson,
Gen. Counsel -
Meredith Kaya,
Sr. VP, Investor Relations & Strategic Fin. -
James G. Chopas CPA,
VP, Corp. Controller & Chief Accounting Officer -
Dr. Lukas Scheibler M.D., Ph.D.,
Chief Innovation Officer -
Karen Lewis,
Chief People Officer -
Nur Nicholson,
Chief Technical Operations Officer -
Dr. Federico Grossi M.D., Ph.D.,
Co-Founder & Chief Medical Officer -
Nur Nicholson,
Chief Technical Officer -
Karen Lewis,
Chief People Officer -
Venture Investments Ltd Mor...,
10% owner -
Lucia Celona,
See Remarks -
Ahmad Sadr,
See Remarks -
Jeffrey Eisele,
Chief Development Officer -
Mark Jeffrey De Long,
Chief Business & Strat Officer -
James George Chopas,
VP/Chief Accounting Officer -
Caroline Baumal,
Chief Medical Officer